Navigation Links
China-Biotics Hosted its First Investor Day Event
Date:9/20/2010

China-Biotics Hosted its First Investor Day Event -- SHANGHAI, Sept. 20 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Supplementary Medicine Click to view news release full screen  

China-Biotics Hosted its First Investor Day Event

 

SHANGHAI, Sept. 20 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics" or "the Company"), the leading developer, manufacturer and distributor of probiotics products in China, today hosted its first investor day with a group of investors and analysts in Shanghai.

In the morning, the company provided a short corporate presentation and showed television commercials for the company's Shining products. Samples of China-Biotics' bank statements, tax returns and retail outlet lease agreements were made available and reviewed by investors and analysts who attended the event. Some distributors of Shining retail products also attended the morning meeting followed by a question and answer session.

Participants of the investor day also visited retail outlets and a mall where customers can purchase China-Biotics' Shining brand products.

An important part of the investor day includes tours to the Pudong and Qingpu production plants as well as the research and development center recently moved into the brand-new office building in Qingpu. The department heads from research and development, production and sales in the bulk additive facility also addressed the investment group. Some of China-Biotics' bulk additive product customers from the dairy and animal feed industries also came to discuss the Company's products and their uses, and answered some of the investors' questions.

Mr. Jinan Song, China-Biotics' Chairman and Chief Executive Officer, concluded the investor day with further discussion on Chinese probiotics market dynamics and long-term growth strategy, particularly for the bulk business of China-Biotics.

Mr. Song commented, "Today, we have raised our level of transparency to a new level. Over 40 investors and analysts have had opportunities to discuss the Company face-to-face with our management, and our retail and institutional customers as well as distributors. We believe that we have made great efforts to enhance our investors' confidence by showing the integrity of our management, financials and operations."

About China-Biotics

China-Biotics, Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk products to institutional customers such as dairy and animal feed producers, as well as pharmaceutical companies. In February 2010, China- Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement

The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward- looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," "continue," or the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 17 and elsewhere in the Company's 2010 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward- looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward-looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.

For more information, please contact: China-Biotics, Inc. Travis Cai Chief Financial Officer Email: traviscai@chn-biotics.com Grayling Kevin Theiss / Shiwei Yin Tel: +1-646-284-9409 Email: kevin.theiss@grayling.com shiwei.yin@grayling.com
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
3. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
4. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
5. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
6. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
7. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
8. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
9. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
10. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
11. China-Biotics, Inc. Appoints New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):